RMSBG has a dedicated team of professionals that are experienced in
providing audit, accounting and tax services to the life sciences and
biotech industry. We have worked in many different segments of this
industry including; medical research and development, pharmaceutical,
medical devices and laboratories. We understand and assist
our life sciences and biotech clients with accounting and tax issues
relating to:
- Development stage company reporting
- Financing arrangements - debt and equity
- Research and development costs (R&D)
- Patents and other intangible assets
- Stock based compensation
- Revenue recognition and complex licensing agreements
We are experienced with working with start-ups as well as established
life sciences companies. As a PCAOB registered firm, we audit publicly
traded companies in the life sciences industry. We are experienced in
the IPO process and we can continue our relationship with your firm as it
goes from a privately held company to a publicly traded company.
RMSBG is focused on guiding life sciences and biotech companies through
the maze of accounting pronouncements affecting their fund raising
efforts, especially in the complex areas of accounting for debt and
equity transactions such as convertible debt, convertible preferred stock
and issuance of warrants and PIPE transactions. We are experienced in
helping clients with issues related to beneficial conversion features,
embedded derivatives, stock based compensation, and the myriad of
disclosures required in the financial statements.
We are familiar with outsourced R&D and collaboration arrangements,
including such issues as accounting for prepaid and accrued R&D costs,
and milestone payments.
Accounting for patents, goodwill and intangibles is another industry
specific area that we have experience in and are aware of the issues
related to capitalization, impairments, purchase price allocations and
acquired in-process R&D.
Revenue recognition is another complex area for biotech companies,
especially for licensing intellectual property, and our firm is versed in
the various accounting pronouncements in this area, including SEC Staff
Accounting Bulletins and FASB Emerging Issue Task Force consensuses.
We also provide consulting services to our life sciences and biotech
clients by assisting in the private and public offering process, debt
financing, merger and acquisition advisory work, valuation activities,
and internal control guidance.
Back to Top
|
